Harbor Therapeutics, Inc.

Erin Olson

Steven K White

Keith Lorimer

Brenton Skylar Wolfe

The invention provides and describes solid state 17&#x3b1;-ethynyl-5&#x3b1;-androstane-3&#x3b1;,17&#x3b2;-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17&#x3b1;-ethynyl-5&#x3b1;-androstane-3&#x3b1;,17&#x3b2;-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17&#x3b1;-ethynyl-5&#x3b1;-androstane-3&#x3b1;,17&#x3b2;-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17&#x3b1;-ethynyl-5&#x3b1;-androstane-3&#x3b1;,17&#x3b2;-diol and uses of such formulations in treating the described conditions.

Growing community of inventors

San Diego, CA, United States of America

Erin Olson